Compare RELL & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | TTRX |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.6M | 138.1M |
| IPO Year | N/A | N/A |
| Metric | RELL | TTRX |
|---|---|---|
| Price | $10.85 | $4.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 80.1K | 64.6K |
| Earning Date | 01-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 71.90 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $212,588,000.00 | N/A |
| Revenue This Year | $5.91 | N/A |
| Revenue Next Year | $13.64 | N/A |
| P/E Ratio | $195.14 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $7.57 | $2.57 |
| 52 Week High | $13.88 | $26.50 |
| Indicator | RELL | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | N/A |
| Support Level | $10.43 | N/A |
| Resistance Level | $11.06 | N/A |
| Average True Range (ATR) | 0.43 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 54.85 | 0.00 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.